Wikipedia -WSS

Wikipedia

author：leisure time 2025-09-29 21:13:39 - browse：5

Aduhelm, a pioneering treatment for Alzheimer’s disease that collapsed under corporate mistakes and regulatory controversy, is now a cautionary tale in pharmaceutical history.

This week Biogen said it would no longer sell or study the medicine, which first won approval in 2021, ending an era for one of biotech’s storied companies and leaving the rest of the industry to piece together the lessons of a would-be blockbuster that never took off.

STAT reporters took a stab at the Aduhelm legacy — for biotech, Biogen, and Alzheimer’s research — on a recent episode of the Readout LOUD. Here’s an edited transcript of that conversation.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： As demand for Covid shots wanes, Moderna seeks its next success
Next article： Mega Millions jackpot grows to $720 million ahead of Friday's drawing

explore

WSS

First Opinion Podcast: How to protect health care in times of war

Cassava reveals details — and problems — with Alzheimer's study

Florida babysitter arrested over hot car death, authorities say

Biden White House, tech companies launch new safeguards around emerging AI technology

FDA approves Eli Lilly ulcerative colitis treatment Omvoh

Why Sanofi got shellacked over its spinoff

hotspot

Wikipedia

focus

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Hospitals warn Medicare's drug payment fix is ‘unlawful’

How one medical school became remarkably diverse

Dispute over threat of extinction posed by artificial intelligence looms over surging industry

Hollywood unions extend contract negotiations for actors

Study: Misdiagnosis causes 800,000 deaths, serious disabilities a year in U.S.

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Cassava reveals details — and problems — with Alzheimer's study

Anesthesiologist group: stop taking Ozempic before surgery

Eli Lilly to pay $200M for Beam’s stake in gene

leisure time

Paying for Covid pills will soon shift to insurers

Why the advice to take all your antibiotics may be wrong

Maker of FluMist seeks to allow at

Grand jury probing Trump's efforts to overturn 2020 election did not meet Friday: Sources

WHO may add ‘noma' to its list of neglected tropical diseases

Hey, doctors: Don't be no

explore

explore

explore

focus